Cardiovascular Systems Company Profile (NASDAQ:CSII)

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.05) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.05). The business had revenue of $52.10 million for the quarter, compared to analyst estimates of $51.13 million. Cardiovascular Systems had a negative net margin of 3.72% and a negative return on equity of 4.36%. The company's revenue was up 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.31) EPS. View Cardiovascular Systems' Earnings History.

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Cardiovascular Systems.

Cardiovascular Systems updated its fourth quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of ($0.06)-($0.04) for the period, compared to the Thomson Reuters consensus estimate of ($0.03). The company issued revenue guidance of $51.5-$52.5 million, compared to the consensus revenue estimate of $53.79 million.

6 brokers have issued 1-year price targets for Cardiovascular Systems' shares. Their predictions range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' stock price to reach $34.40 in the next year. View Analyst Ratings for Cardiovascular Systems.

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

• 1. Needham & Company LLC analysts commented, "We are reiterating our Buy rating on CSII, raising our FY18 and FY19 estimates, and raising our price target to $37 from $32. Over the next few quarters, we expect revenue growth to slow due to tougher comps but we expect earnings upside to drive shares higher. We expect the ECLIPSE trial and Japan to drive strong coronary growth in coming years." (7/14/2017)
• 2. According to Zacks Investment Research, "Cardiovascular Systems posted solid second quarter of fiscal 2017, with both earnings and sales ahead of the respective Zacks Consensus Estimate. We are also encouraged by the company’s improving operating expense scenario, driving year-over-year rise in the earnings figure. Per management, the company delivered improved results over the past four quarters, showing major progress in driving revenue growth, while moving toward positive cash flow and profitability. On the flip side, share price trend over the past one month that traded below the broader Medical Products Industry. The company operates in the competitive medical device industry. Additionally, the company expects to witness net loss in the next third quarter a rise in its general and administrative expenses with growth in its business. All these indicate that there is no near term respite from the continuing operating loss structure." (3/16/2017)

Some companies that are related to Cardiovascular Systems include Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), AtriCure (ATRC), Intersect ENT (XENT), CryoLife (CRY), Meridian Bioscience (VIVO), Consort Medical plc (CSRT), Landauer (LDR), Antares Pharma (ATRS), Exactech (EXAC) and Invacare Corporation (IVC).

Cardiovascular Systems' management team includes the folowing people:

• Scott R. Ward, Chairman of the Board, President, Chief Executive Officer
• Laurence L. Betterley, Chief Financial Officer
• Kevin J. Kenny, Chief Operating Officer
• Martha Goldberg Aronson, Independent Director
• Scott A. Bartos, Independent Director
• Brent G. Blackey, Independent Director
• Edward M. Brown, Independent Director
• William E. Cohn M.D., Independent Director

Cardiovascular Systems' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.16%), First Quadrant L P CA (0.13%), Meeder Asset Management Inc. (0.09%), Quotient Investors LLC (0.06%), Fox Run Management L.L.C. (0.03%) and US Bancorp DE (0.03%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA and Bank of Montreal Can. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn. View Insider Buying and Selling for Cardiovascular Systems.

Cardiovascular Systems' stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Winslow Evans & Crocker Inc.. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cardiovascular Systems stock can currently be purchased for approximately $32.05.